Characteristic | Dexmedetomidine group (n = 80) | Placebo group (n = 80) | P value |
---|---|---|---|
Age, median (IQR), year | 59 (55, 65) | 62 (56, 67) | 0.123 |
Sex, No. (%) | |||
 Male | 51 (63.8) | 53 (66.3) | 0.740 |
 Female | 29 (36.3) | 27 (33.8) |  |
Hight, median (IQR), cm | 168.0 (160.0, 171.5) | 166.00 (160.0, 172.0) | 0.832 |
Weight, median (IQR), kg | 60.50(55.0, 69.5) | 62.00 (57.5, 71.0) | 0.284 |
BMI, median (IQR) a | 22.59 (20.36, 24.16) | 22.90 (21.03, 25.10) | 0.283 |
ARISCAT score b | |||
 Intermediate risk, No. (%) | 77 (96.3) | 79 (98.8) | 0.311 |
 High risk, No. (%) | 3 (3.8) | 1 (1.3) |  |
 Mean (SD) | 28.36 (4.82) | 28.32 (4.81) |  |
ASA physical status classification, No. (%) c | |||
 1 | 16 (20.0) | 17 (21.3) | 0.216 |
 2 | 61 (76.3) | 63(78.7) |  |
 3 | 3 (3.8) | 0 (0) |  |
NYHA heart failure class, No. (%) d | |||
 I | 47 (58.8) | 51 (63.7) | 0.516 |
 II | 33 (41.2) | 29 (36.2) |  |
Tobacco use, No. (%) | 31 (38.8) | 29 (36.2) | 0.744 |
Alcohol use, No. (%) e | 25 (31.3) | 21 (26.3) | 0.485 |
Preoperative SpO2, No. (%) | |||
  ≥ 96 | 67 (83.8) | 68 (85.0) | 0.975 |
 91–95 | 12 (15.0) | 11 (13.8) |  |
  ≤ 90 | 1 (1.3) | 1 (1.3) |  |
Preoperative anemia (Hb ≤ 10 g/dl), No. (%) | 9 (11.3) | 5 (6.3) | 0.263 |
 Mean (SD), g/dl | 13.54 (2.03) | 13.72 (1.92) |  |
Comorbidity | |||
 Arterial hypertension, No. (%) | 27 (33.8) | 24 (30.0) | 0.611 |
 Diabetes, No. (%) | 9 (11.3) | 12 (15.0) | 0.483 |
 Coronary artery disease, No. (%) | 8 (10.0) | 4 (5.0) | 0.230 |
 Arrhythmia, No. (%) | 6 (7.5) | 6 (7.5) | 1.000 |
 COPD, No. (%) | 1 (1.3) | 4 (5.0) | 0.173 |
 Asthma, No. (%) | 0 (0.0) | 1 (1.3) | 0.316 |
Preoperative abnormalities on chest radiography, No. (%) | 4 (5.0) | 8 (10.0) | 0.230 |
Active cancer, No. (%) | 69 (86.3) | 70 (87.5) | 0.815 |